There has been concern that GH treatment of children might increase meningioma risk. Results of published studies have been inconsistent and limited.
Growth hormone (GH) is prescribed for an increasing range of indications, but there has been concern that it might raise cancer risk. Published data are limited.
Modern treatment of Hodgkin’s lymphoma (HL) has transformed its prognosis but causes late effects, including premature menopause. Cohort studies of premature menopause risks after treatment have been relatively small, and knowledge about these risks is limited.